How Denosumab (Prolia) Affects DEXA Bone Density

Mechanism: How Denosumab Changes Bone Density on DEXA

Denosumab is a fully human monoclonal antibody that binds RANK ligand (RANKL), the protein osteoblasts produce to activate osteoclasts. By neutralizing RANKL, denosumab blocks osteoclast formation, function, and survival. Bone resorption drops within days of a single 60 mg subcutaneous dose 1.

This resorption block shifts the balance of bone turnover toward net formation. Serum C-telopeptide (CTX), a resorption marker, falls by approximately 85% within one month of injection and remains suppressed until the drug clears around month five 2. Because DEXA measures areal bone mineral density in grams per square centimeter, the reduced removal of mineralized bone directly raises the T-score at every scanned site. The pharmacologic half-life of denosumab is roughly 25 to 28 days, but its biologic effect on resorption markers persists for the full six-month dosing interval 2. That sustained suppression is why the every-six-month schedule works.

Unlike bisphosphonates, denosumab does not embed in the bone matrix. It circulates, binds soluble and membrane-bound RANKL, and is cleared by the reticuloendothelial system. This means its effect is fully reversible. Stop the injections, and osteoclast activity rebounds within months.

FREEDOM Trial: The Landmark BMD Data

The key evidence comes from FREEDOM, a randomized, double-blind, placebo-controlled trial that enrolled 7,868 postmenopausal women aged 60 to 90 with T-scores between -2.5 and -4.0 at the lumbar spine or total hip 1.

Over 36 months, denosumab 60 mg every six months produced these DEXA gains versus placebo 1:

• Lumbar spine: +9.2%
• Total hip: +6.0%
• Femoral neck: +4.8%
• Distal one-third radius: +1.4%

These differences were statistically significant at every time point measured (P<0.001 for all sites at 36 months). The placebo group lost BMD at the spine and hip over the same period. The 2020 Endocrine Society clinical practice guideline noted that "denosumab produces the largest and most consistent BMD gains of any currently approved antiresorptive agent" 3.

Fracture endpoints confirmed that the density gains translated into clinical protection. Vertebral fractures fell 68%, hip fractures fell 40%, and nonvertebral fractures fell 20% relative to placebo over 36 months 1.

BMD Gains Beyond Three Years: The FREEDOM Extension

The open-label FREEDOM Extension followed participants who continued denosumab for up to 10 total years of therapy (N=4,550 who crossed over or continued) 4. BMD did not plateau. Gains were continuous and cumulative:

• Lumbar spine: +21.7% at 10 years (from original FREEDOM baseline)
• Total hip: +9.2% at 10 years
• Femoral neck: +9.0% at 10 years

No other antiresorptive therapy has demonstrated continuous BMD accrual over a full decade in a published extension study. By comparison, alendronate produces most of its lumbar spine BMD gain within the first three to four years, with minimal additional accrual afterward 5. This sustained trajectory is one reason the American Association of Clinical Endocrinology (AACE) 2020 guideline identifies denosumab as a first-line option for patients with very high fracture risk who may need prolonged therapy 6.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, stated in a 2017 review of the Extension data: "The progressive increase in BMD with continued denosumab therapy, without evidence of a plateau, is unique among antiresorptive agents and supports the concept that RANKL inhibition can restore bone density toward premenopausal levels in many patients" 4.

Head-to-Head Against Bisphosphonates: DEXA Outcomes Compared

Several trials have directly compared denosumab to oral and intravenous bisphosphonates. The DECIDE study (N=1,189) randomized postmenopausal women already on alendronate to either continue alendronate 70 mg weekly or switch to denosumab 60 mg every six months 7. At 12 months, the denosumab group gained significantly more BMD at the total hip (+1.90% vs. +1.05%; treatment difference 0.85%, P<0.0001) and lumbar spine (+3.03% vs. +1.85%) 7.

The STAND trial (N=504) evaluated treatment-naive women randomized to denosumab or alendronate for 12 months 8. Denosumab produced greater BMD increases at the total hip (+3.5% vs. +2.6%) and all other measured sites 8.

Against zoledronic acid, the comparison is closer. A 2014 meta-analysis found denosumab produced modestly greater BMD gains at the lumbar spine and total hip than zoledronic acid, though the absolute differences were small (approximately 0.5 to 1.0 percentage points at 12 months) 9. Both agents are classified as "strong" antiresorptives in the AACE fracture-risk algorithm 6.

When to Check DEXA on Denosumab: Monitoring Timeline

The Endocrine Society and AACE recommend a baseline DEXA before starting denosumab, with follow-up scans every one to two years during therapy 3. A practical monitoring schedule looks like this:

Baseline (before first injection): DEXA of lumbar spine, total hip, and femoral neck. This establishes the reference values for tracking percentage change over time.

12 months: First follow-up DEXA. Most patients will show a measurable gain of 3 to 5% at the lumbar spine. The ISCD (International Society for Clinical Densitometry) defines the least significant change for spine DEXA at approximately 3 to 5% depending on the machine, so a single 12-month scan may or may not exceed the precision threshold 10.

24 months: By this point, spine BMD gains typically exceed 5%, well above the least significant change. This scan is the most informative early indicator of treatment response 1.

Every 1 to 2 years thereafter: Continued monitoring confirms ongoing accrual and adherence. Because denosumab requires on-time dosing every six months, a DEXA showing unexpected BMD loss should prompt a conversation about missed or delayed injections.

Bone turnover markers (CTX and P1NP) can supplement DEXA. CTX should drop by 50% or more within three months of the first injection. This early biochemical check can flag non-response or adherence problems months before a DEXA would show changes 2.

What Happens to DEXA Scores When You Stop Denosumab

This is the most clinically consequential aspect of denosumab therapy. The drug's effect is fully reversible. Once injections stop, bone resorption markers rebound above pretreatment levels within three to six months, a phenomenon called the "rebound effect" 11.

BMD drops rapidly. In a post-hoc analysis of FREEDOM participants who discontinued after two to six denosumab doses, lumbar spine BMD returned to baseline within 12 months, and some patients lost more bone than they had gained 11. Multiple vertebral fractures have been reported in patients who stopped denosumab without transitioning to a bisphosphonate 12.

The 2024 position statement from the European Calcified Tissue Society recommends that all patients who discontinue denosumab receive at least one year of oral or intravenous bisphosphonate to blunt the rebound 13. Common transition protocols include:

• Oral alendronate 70 mg weekly for 12 months, started six months after the last denosumab injection
• A single infusion of zoledronic acid 5 mg, timed six to seven months after the last denosumab dose, with DEXA and CTX monitoring at 12 months to confirm suppression

Dr. Felicia Cosman, professor of clinical medicine at Columbia University and a lead author of the National Osteoporosis Foundation's Clinician's Guide, has stated: "No patient should discontinue denosumab without a planned transition to an alternative antiresorptive. The rebound phenomenon is real, reproducible, and preventable" 12.

Factors That Influence the Magnitude of BMD Response

Not every patient on denosumab gains the same amount of bone density. Several factors modify the expected DEXA response.

Baseline T-score: Patients starting with lower BMD tend to show larger absolute percentage gains. In a FREEDOM subanalysis, women with baseline lumbar spine T-scores below -3.5 gained more than women closer to -2.5 14. The bone is further from its physiologic ceiling, so the net effect of halting resorption is proportionally greater.

Prior antiresorptive therapy: Patients switching from a bisphosphonate to denosumab still gain additional BMD, but the incremental gain above what bisphosphonates achieved is smaller than starting denosumab de novo. The DECIDE trial showed this clearly: women who switched gained approximately 1% more at the hip than those who stayed on alendronate, compared to 3 to 6% gains in treatment-naive patients from FREEDOM 7.

Vitamin D status: Denosumab labeling requires correction of hypocalcemia before starting therapy. Patients with 25-hydroxyvitamin D levels below 20 ng/mL may have blunted BMD responses and higher risk of symptomatic hypocalcemia 15. The FDA prescribing information recommends adequate calcium (at least 1,000 mg daily) and vitamin D (at least 400 IU daily) supplementation for all patients on Prolia 15.

Adherence to the six-month schedule: Delayed injections beyond seven months allow partial recovery of osteoclast activity. A retrospective cohort study of 2,594 denosumab-treated patients found that delays of more than eight weeks beyond the scheduled dose were associated with a 3.4-fold increased risk of vertebral fracture compared to on-schedule dosing 16.

Clinical Significance: When BMD Gains Change Management Decisions

A rising DEXA on denosumab does not just confirm the drug is working. It can change treatment classification. A patient who starts with a femoral neck T-score of -2.8 and gains 6% over three years may cross back above -2.5, the densitometric threshold for osteoporosis 3. That shift can affect insurance coverage determinations, fracture risk calculator outputs (FRAX uses femoral neck BMD as an input), and clinical decisions about duration of therapy.

The AACE 2020 guideline recommends treating to a target, specifically a T-score above -2.5 at the hip, rather than treating for a fixed duration 6. Under this framework, serial DEXA results directly guide whether to continue denosumab, transition to a bisphosphonate for consolidation, or consider an anabolic agent if targets are not reached.

For patients already on denosumab who show an unexpected decline in BMD, the differential includes missed doses, malabsorption of calcium or vitamin D, new hyperparathyroidism, or scan-to-scan measurement variability (the ISCD estimates lumbar spine precision error at 1.0 to 1.5% on modern DXA machines) 10. A single lower value should be confirmed with a repeat scan and bone turnover markers before changing therapy.